KPV
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
KPV is a tripeptide — a short chain of just three amino acids: lysine, proline, and valine (Lys-Pro-Val). It represents the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring signaling molecule, and is studied mainly for its anti-inflammatory properties.
Interest in KPV comes largely from the observation that this small fragment appears to carry much of the anti-inflammatory activity of the larger α-MSH hormone, but without the pigment-related effects associated with the full-length peptide. That has made it a focus in research on the gut, the immune system, and inflammatory skin conditions.
Most of the evidence to date comes from cell and animal models. Human clinical data is limited, and KPV is not approved by any major regulator for therapeutic use.
How it works
In preclinical studies, KPV is reported to dampen inflammatory signaling inside cells, including effects on the NF-κB and MAP-kinase pathways, which in turn is associated with reduced output of pro-inflammatory cytokines in intestinal and other epithelial models. In the gut specifically, researchers have described uptake of KPV through the PepT1 peptide transporter, which is expressed in intestinal and immune cells.
Because it is derived from α-MSH, KPV is also studied for antimicrobial activity in laboratory settings. The precise mechanisms in humans are not established.
Reported benefits
- Reduced intestinal inflammation in colitis models (animal and cell data)
- Support for immune modulation and mucosal health
- Interest in inflammatory skin conditions (early, preclinical)
- Antimicrobial activity observed in laboratory studies
These are reported and studied effects, not guaranteed outcomes.
Considerations & side effects
Because robust human trials are lacking, the safety profile of KPV in people is not well characterized, and long-term effects are unknown. Much of the current evidence is preclinical, so findings from cell and animal models may not translate directly to humans.
Product purity varies widely in the research-chemical market. KPV is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is KPV?
KPV is a tripeptide made of the amino acids lysine, proline, and valine (Lys-Pro-Val). It corresponds to the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH) and is studied for its anti-inflammatory properties.
Is KPV FDA-approved?
No. KPV is not approved by the FDA or any major regulator for human therapeutic use, and is sold for research purposes only.
How is KPV different from alpha-MSH?
KPV is the small C-terminal tail of α-MSH. In research it is reported to retain much of the parent hormone's anti-inflammatory activity while lacking the pigment-darkening (melanocortin) effects of the full-length peptide.
What is KPV studied for?
Most preclinical work has focused on gut inflammation — such as colitis models — along with immune modulation and inflammatory skin conditions. Human clinical data is limited.
References
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. ↗
- Getting SJ, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. ↗
- Singh M, Mukhopadhyay K. Alpha-Melanocyte Stimulating Hormone: An Emerging Anti-Inflammatory Antimicrobial Peptide. ↗
Related compounds
Body Protection Compound-157. A pentadecapeptide derived from human gastric juice. Known for tissue healing, gut health, and injury recovery.
Four-peptide regenerative blend combining GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg), and TB-500 (10mg). Advanced healing and anti-inflammatory protocol. Sold as a single 80mg pre-mixed vial.
An 8-amino-acid tight-junction regulator that acts as a zonulin antagonist to restore intestinal barrier function and reduce 'leaky gut' permeability. The most clinically advanced peptide for celiac disease; taken orally before meals.